Does MTNR1B rs10830963 CG with sleep-disordered breathing increase glucose vulnerability?

The combination of the MTNR1B rs10830963 CG genotype and sleep-disordered breathing (SDB) represents a compounding challenge to metabolic health, presenting distinct genetic and physiological pathways to impaired glucose regulation.

Genetic and molecular mechanisms

• The MTNR1B rs10830963 variant upregulates melatonin receptor 1B expression directly in pancreatic beta-cells.
• This receptor overexpression sensitizes beta-cells to the inhibitory effects of melatonin, suppressing cAMP signaling and blunting early-phase insulin release.
• This altered timing delays the insulin response necessary for immediate post-challenge glucose disposal, directly increasing fasting and postprandial glucose levels.

Sleep-disordered breathing and insulin resistance

• SDB acts as a potent environmental stressor that compromises systemic insulin sensitivity.
• The primary pathophysiological consequences of SDB—including intermittent nocturnal hypoxia, elevated sympathetic nervous system activity, and sleep fragmentation—directly worsen overnight insulin resistance.
• This nocturnal resistance impairs efficient overnight glucose clearance, driving sustained circulating glucose levels.

Combined glucose vulnerability

• The co-occurrence of these two factors creates a dual-pathway metabolic burden.
• The genetically driven defect in early-phase insulin secretion timing occurs alongside SDB-induced overnight insulin resistance, cumulatively exacerbating overall glucose vulnerability.

Bottom line

• Key takeaway: Although the MTNR1B rs10830963 variant does not cause SDB, their combination severely compounds metabolic strain, as impaired melatonin-linked insulin timing and heightened overnight insulin resistance interact to elevate fasting plasma glucose and increase the risk of type 2 diabetes.